The Other Side: Scott Pantel

Released on May 26, 2020 | Written by Joe Mullings of The Mullings Group

Scott Pantel, the CEO of Life Science Intelligence and I discussed the emerging sales activities coming on the line as the first glimpse of some sort of a horizon declares itself in the MedTech industry.

Re-entry guidelines (included in the link below) were published this past week for medical device reps into healthcare facilities.

Certainly critical care, infection management, and drug delivery will be front and center on re-entry, but where will ortho, cardiology, and other interventional categories fall in the pecking order?

Who is first at-bat and who has prepared their sales and clinical teams to go back into facilities? How are they going to integrate virtual activities into their playbooks?

Full video interview below.

Re-entry Guidance for Health Care Facilities and Medical Device Representatives

Editor’s Note:

Life Science Intelligence is an information service company that provides preeminent MedTech market data backed by world-class support, industry veterans, and trusted advisors.

Learn more about LSI here:


Written by

The Mullings Group